Tian Zhang, Director of Clinical Research at UT Southwestern Medical Center, shared a post on X:
“Thorough, balanced discussion from Rana McKay of neoadjuvant vs adjuvant trials in kidney cancer – we need to consider all risks and benefits when giving early treatment.”
More posts featuring Rana McKay on OncoDaily.
